Item 8.01 Other Events.
On September 13, 2021, Adaptimmune Therapeutics plc ("Adaptimmune") issued a
press release announcing updated data from its Phase 1 SURPASS trial in multiple
solid tumors to be presented in a digital poster at the European Society for
Medical Oncology (ESMO) annual meeting. The poster will be displayed on the ESMO
congress website on September 16, 2021. The Company has also released a video of
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer, and Elliot Norry,
Adaptimmune's Chief Medical Officer, describing these data in greater detail.
The press release is furnished as Exhibit 99.1 and is incorporated by reference
herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description of Exhibit
99.1 Press release dated September 13, 2021
104 Cover Page Interactive Date File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses